NASDAQ: COEPCoeptis Therapeutics Holdings Inc Stock
$8.36-0.04 (-0.48%)
Updated Jun 13, 2025
COEP Price
$8.36
Fair Value Price
-$0.45
Market Cap
$29.38M
52 Week Low
$2.31
52 Week High
$13.70
P/E
-1.62x
P/B
4.53x
P/S
457.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$62.87k
Earnings
-$9.87M
Gross Margin
28.2%
Operating Margin
-15,273.15%
Profit Margin
-15,698%
Debt to Equity
0.93
Operating Cash Flow
-$7M
Beta
0.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COEP Overview
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COEP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COEP
Ranked#149 of 464
Ranked#149 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important COEP news, forecast changes, insider trades & much more!
COEP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COEP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COEP ($8.36) is overvalued by 1,957.95% relative to our estimate of its Fair Value price of -$0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COEP ($8.36) is not significantly undervalued (1,957.95%) relative to our estimate of its Fair Value price of -$0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COEP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COEP due diligence checks available for Premium users.
Valuation
COEP fair value
Fair Value of COEP stock based on Discounted Cash Flow (DCF)
Price
$8.36
Fair Value
-$0.45
Undervalued by
1,957.95%
COEP ($8.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COEP ($8.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COEP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COEP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.62x
Industry
-108.97x
Market
31.36x
COEP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.53x
Industry
4.66x
COEP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COEP's financial health
Profit margin
Revenue
$62.9k
Net Income
-$3.1M
Profit Margin
-4,863.3%
COEP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
COEP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.5M
Liabilities
$6.0M
Debt to equity
0.93
COEP's short-term liabilities ($5.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COEP's short-term assets ($4.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COEP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
$6.1M
COEP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COEP vs Biotech Stocks
Coeptis Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.